Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience

Annals of Surgical Oncology

Volumn 22, Issue 13, 2015, Pages 4211-4216

  Musella, A ^a   Marchetti, C ^a   Palaia, I ^a   Perniola, G ^a   Giorgini, M ^a   Lecce, F ^a   Vertechy, L ^a   Iadarola, R ^a   De Felice, F ^a   Monti, M ^a   Muzii, L ^a   Angioli, R ^b   Panici, P Benedetti ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PLATINUM;

ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CARCINOSARCOMA; CLEAR CELL CARCINOMA; CONTROL GROUP; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; INTESTINE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUCINOUS CYSTIC NEOPLASM; OVARY CANCER; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PELVIS; PELVIS LYMPH NODE; PERITONEUM; POSTOPERATIVE COMPLICATION; RELAPSE; VEIN INJURY; WORK EXPERIENCE; WOUND DEHISCENCE; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE; ENDOMETRIAL NEOPLASMS; FOLLOW UP; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR INVASION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; CYTOREDUCTION SURGICAL PROCEDURES; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84947125586     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4523-2     Document Type: Article

References (24)

1. American Cancer Society: Cancer Facts and Figures 2014. Atlanta: American Cancer Society, 2014.
2. Salani R, Backes FJ, Fung K, Holschneider CH, Parker LP, Bristow RE, Goff BA. Post treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204:466–78.
3. Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database Syst Rev. 2014;2:CD009786.
4. Rettenmaier NB, Rettenmaier CR, Wojciechowski T, Abaid LN, Brown JV III, Micha JP, Goldstein BH. The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review. Br J Cancer. 2010;103:1657–62.
5. Schorge JO, Wingo SN, Bhore R, Heffernan TP, Lea JS. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet. 2010;108:123–7.
6. Frederick PJ, McQuinn L, Milam MR, et al. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:831–6.
7. Petrillo M, Fagotti A, Ferrandina G, et al. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol. 2013;131:36–41.
8. Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, Bristow RE. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109:685–91.
9. Magrina JF, Cetta RL, Chang YH, Guevara G, Magtibay PM. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecol Oncol. 2013;129:336–40.
10. Fagotti A, Petrillo M, Costantini B, et al. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series. Gynecol Oncol. 2014;132:303–6.
11. Gallotta V, Fagotti A, Fanfani F, et al. Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc. 2014;28:1808–15.
12. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144–53.
13. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol. 2002;99:1008–13.
14. Friedman RL, Eisenkop SM, Wang HJ. Secondary cytoreductive surgery for recurrent ovarian cancer. Cancer. 1995;76:1606–14.
15. Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, Graeff H. Radical surgical procedure improves survival time in patients with ovarian cancer. Cancer. 1992;70:2129–36.
16. Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol. 1989;34:334–8.
17. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist. 2000;5:26–35.
18. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011;71:1397–412.
19. Petrillo M, Pedone Anchora L, Tortorella L, et al. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. Gynecol Oncol. 2014;134:257–61.
20. Blanchard P, Plantade A, Pages C, Afchain P, Louvet C, Tournigand C, de Gramont A. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors. Gynecol Oncol. 2007;104:41–5.
21. BenedettiPanici P, Perniola G, Angioli R, et al. Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery. Int J Gynecol Cancer. 2007;17:1245–51.
22. Santillan A, Karam AK, Li AJ, et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol. 2007;104:686–90.
23. Uzan C, Morice P, Rey A, et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann Surg Oncol. 2004;11:658–64.
24. Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer. 2006;42:2296–302.